Mary Grecco

Lung Cancers Today

Patients with metastatic NSCLC (mNSCLC) who receive first-line anti-PD-L1-based IO may achieve durable disease control, but without driver alterations, most will require treatment with additional lines of therapy (LOT). Results from a study that evaluated treatment patterns and real-world clinical outcomes after concurrent or sequential anti-PD-L1 and platinum-doublet chemotherapy (PDC), a setting with currently limited effective options, were presented at the 2023 North America Conference on Lung Cancer.
The study included patients with mNSCLC (without evidence of EGFR/ALK/ROS1 alterations) who experienced disease progression on or after anti-PD-L1 and PDC, initiated subsequent LOT between 2017 and 2021, and had an ECOG PS of 0-2 at LOT initiation (index date). The median patient age was 63 years, 63.1% were male, and 50.4% were White. Most (87.2%) patients had de novo mNSCLC and an ECOG PS of 0-1 (81.6%). Regarding disease progression, 47.5% had liver metastases and 15.6% had brain metastases. The researchers assessed OS and time to treatment discontinuation (TTD) using Kaplan-Meier analysis.
Results showed that most patients had disease progression on anti-PD-L1 and PDC as first-line treatment (90.1%). The most common regimens received as subsequent treatment were nonplatinum chemotherapy (26.2%), anti-PD-L1 monotherapy (18.4%), PDC plus anti-VEGF(R) (9.2%), and nonplatinum chemotherapy plus anti-VEGF(R) (7.1%). The researchers found 6- and 12-month OS rates to be 71.4% and 43.8%, respectively, with a median OS of 9.8 months. Median TTD was 5.8 months.
“Various treatment regimens were used among mNSCLC patients with disease progression after treatment with anti-PD-L1 and PDC. Poor clinical outcomes demonstrate an unmet clinical need that warrants more efficacious treatment options for patients with mNSCLC who progressed on anti-PD-L1 and PDC,” the researchers concluded.
Source: Liu SV, Dasgupta A, Latremouille-Viau D, et al. Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US. Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

Patients with metastatic NSCLC (mNSCLC) who receive first-line anti-PD-L1-based IO may achieve durable disease control, but without driver alterations, most will require treatment with additional lines of therapy (LOT). Results from a study that evaluated treatment patterns and real-world clinical outcomes after concurrent or sequential anti-PD-L1 and platinum-doublet chemotherapy (PDC), a setting with currently limited effective options, were presented at the 2023 North America Conference on Lung Cancer.The study included patients with mNSCLC (without evidence of EGFR/ALK/ROS1 alterations) who experienced disease progression on or after anti-PD-L1 and PDC, initiated subsequent LOT between 2017 and 2021, and had an ECOG PS of 0-2 at LOT initiation (index date). The median patient age was 63 years, 63.1% were male, and 50.4% were White. Most (87.2%) patients had de novo mNSCLC and an ECOG PS of 0-1 (81.6%). Regarding disease progression, 47.5% had liver metastases and 15.6% had brain metastases. The researchers assessed OS and time to treatment discontinuation (TTD) using Kaplan-Meier analysis.Results showed that most patients had disease progression on anti-PD-L1 and PDC as first-line treatment (90.1%). The most common regimens received as subsequent treatment were nonplatinum chemotherapy (26.2%), anti-PD-L1 monotherapy (18.4%), PDC plus anti-VEGF(R) (9.2%), and nonplatinum chemotherapy plus anti-VEGF(R) (7.1%). The researchers found 6- and 12-month OS rates to be 71.4% and 43.8%, respectively, with a median OS of 9.8 months. Median TTD was 5.8 months.“Various treatment regimens were used among mNSCLC patients with disease progression after treatment with anti-PD-L1 and PDC. Poor clinical outcomes demonstrate an unmet clinical need that warrants more efficacious treatment options for patients with mNSCLC who progressed on anti-PD-L1 and PDC,” the researchers concluded.Source: Liu SV, Dasgupta A, Latremouille-Viau D, et al. Real-world clinical outcomes after progression with anti-PD(L)1 and chemotherapy in mNSCLC in the US. Abstract of a poster presented at the 2023 North America Conference on Lung Cancer; December 1-3, 2023; Chicago, Illinois.

Lung Cancers Today Editors

MARIPOSA: Amivantamab Plus Lazertinib Versus Osimertinib in EGFR-mutant NSCLC

Lung Cancer

NeoADAURA: Neoadjuvant Osimertinib for Resectable EGFR-mutated NSCLC

Sanjay Juneja, MD

Stephen V. Liu, MD

Millie Das, MD

Eric Singhi, MD

Laura Litwin

The Oncology Forum: Experts Address Questions About Oncology Referrals in Later-Stage NSCLC

Non-Small Cell Lung Cancer

The Oncology Forum: Experts Answer Major Questions About Immunotherapy in NSCLC

The Oncology Forum: Expert Panel Discusses Key Updates in NSCLC

FLAURA2 Trial: Osimertinib Effectively Combats NSCLC

Latest News

Outcomes After Progression With Anti-PD-L1, Chemotherapy in mNSCLC Clinical

NACLC 2023

Patients with metastatic NSCLC who receive first-line anti-PD-L1-based IO may achieve durable disease control.